Page 6 - தலை ஆஃப் பெருநிறுவன தகவல்தொடர்புகள் முதலீட்டாளர் உறவுகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from தலை ஆஃப் பெருநிறுவன தகவல்தொடர்புகள் முதலீட்டாளர் உறவுகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In தலை ஆஃப் பெருநிறுவன தகவல்தொடர்புகள் முதலீட்டாளர் உறவுகள் Today - Breaking & Trending Today

Basilea Pharmaceutica AG: Basilea successfully placed 1 million new registered shares, raising gross proceeds of CHF 45.75 million

Basilea Pharmaceutica AG: Basilea successfully placed 1 million new registered shares, raising gross proceeds of CHF 45.75 million
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Basel Stadt , United States , United Kingdom , Nils Schr , Bryan Garnier , David Veitch , Head Of Corporate Communications Investor Relations , Credit Suisse , Financial Services , Swiss Exchange , Basilea Pharmaceutica Ltd , United Kingdom European Union Withdrawal , Swiss Financial Services , Cantor Fitzgerald , European Union , Swiss Exchange On , Chief Executive Officer , Joint Bookrunners , United Kingdom European Union , European Economic Area , United Kingdom Prospectus Regulation , Markets Act , Financial Promotion , Qualified Investors , Qualified Investor , Basilea Pharmaceutica ,

Investegate |Basilea Pharmaceutica AG Announcements | Basilea Pharmaceutica AG: Basilea launches a private placement of new shares by way of an accelerated bookbuilding

Investegate |Basilea Pharmaceutica AG Announcements | Basilea Pharmaceutica AG: Basilea launches a private placement of new shares by way of an accelerated bookbuilding
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

Basel Stadt , United States , United Kingdom , Nils Schr , Bryan Garnier , Head Of Corporate Communications Investor Relations , Credit Suisse , Financial Services , Basilea Pharmaceutica Ltd , United Kingdom European Union Withdrawal , Swiss Exchange , Swiss Financial Services , Cantor Fitzgerald , European Union , Swiss Exchange On , Pharmaceutica Ltd , Securities Act , Joint Bookrunners , United Kingdom European Union , European Economic Area , United Kingdom Prospectus Regulation , Markets Act , Financial Promotion , Qualified Investors , Qualified Investor , Basilea Pharmaceutica ,

Basilea Pharmaceutica AG: Basilea launches a private placement of new shares by way of an accelerated bookbuilding

Basilea Pharmaceutica AG: Basilea launches a private placement of new shares by way of an accelerated bookbuilding
Basel, Switzerland, February 23, 2021
Basilea Pharmaceutica Ltd ( Basilea or the Company ) announced today the launch of an offering of up to 1 million new registered shares with a par value of CHF 1.00 per share. The net proceeds from this private placement will be used for i) the clinical development of Basilea s clinical oncology drug candidates derazantinib and lisavanbulin, ii) pre-clinical research and development activities, and iii) working capital and other general corporate purposes, including investments in or in-licensing of complementary businesses, products or assets.
The new shares correspond to approximately 8% of Basilea s currently issued share capital and will be issued from the Company s authorized share capital, excluding subscription rights of existing shareholders. The offer price of the new shares will be determined in an accelera ....

Basel Stadt , United States , United Kingdom , Nils Schr , Bryan Garnier , Head Of Corporate Communications Investor Relations , Credit Suisse , Financial Services , Swiss Exchange , Basilea Pharmaceutica Ltd , United Kingdom European Union Withdrawal , Swiss Financial Services , Cantor Fitzgerald , European Union , Basilea Press , Swiss Exchange On , Pharmaceutica Ltd , Securities Act , Joint Bookrunners , United Kingdom European Union , European Economic Area , United Kingdom Prospectus Regulation , Markets Act , Financial Promotion , Qualified Investors , Qualified Investor ,

Basilea Pharmaceutica AG: Basilea reports strong 2020 financial results and significant progress in the clinical pipeline of its oncology assets

Basilea Pharmaceutica AG: Basilea reports strong 2020 financial results and significant progress in the clinical pipeline of its oncology assets
Operating loss reduced by over 50% to CHF 8.2 million
Improved operating cash flow by 15%, CHF 167 million year-end cash and financial investments
Established clinical proof of concept for derazantinib as monotherapy in first cancer indication
2021 guidance: expecting 38% - 51% growth in Cresemba and Zevtera non-deferred revenue contributions, stable expenses and 2021 year-end cash position of
CHF 110 - 120 million
Basel, Switzerland, February 16, 2021
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today its financial results for the financial year ended December 31, 2020.
David Veitch, Chief Executive Officer, said: Despite the coronavirus pandemic, we have remained fully operational and have achieved significant milestones throughout 2020, both in the commercialization of our two marketed brands, Cr ....

United States , Basel Stadt , Nils Schr , Asahi Kasei , Marc Engelhardt , Eli Lilly , David Veitch , Asia Pacific , Cresemba Zevtera , Adesh Kaul , Head Of Corporate Communications Investor Relations , Arqule Inc , Merck Co Inc , Adult Brain Tumor Consortium , Virtual Congress , Biomedical Advanced Research , Human Services , Us Department Of Health , Drug Administration , Basilea Pharmaceutica Ltd , Swiss Exchange , Development Authority , Office Of The , Chief Executive Officer , Chief Financial Officer , Basilea Pharmaceutica ,

Basilea reports strong 2020 financial results and significant progress in the clinical pipeline ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Basilea reports strong 2020 financial results and significant progress in the clinical pipeline .
Basilea Pharmaceutica AGFebruary 16, 2021 GMT
Double-digit growth in Cresemba and Zevtera non-deferred revenue contributions
Operating loss reduced by over 50% to CHF 8.2 million
Improved operating cash flow by 15%, CHF 167 million year-end cash and financial investments
Established clinical proof of concept for derazantinib as monotherapy in first cancer indication
2021 guidance: expecting 38% - 51% growth in Cresemba and Zevtera non-deferred revenue contributions, stable expenses and 2021 year-end cash position of CHF 110 - 120 million
Basel, Switzerland, February 16, 2021
ADVERTISEMENT
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today its financial results for the financial year ended December 31, 2020. ....

Basel Stadt , Nils Schr , Asahi Kasei , Marc Engelhardt , Eli Lilly , David Veitch , Asia Pacific , Cresemba Zevtera , Adesh Kaul , Head Of Corporate Communications Investor Relations , Drug Administration , Basilea Pharmaceutica Ltd , Swiss Exchange , Adult Brain Tumor Consortium , Virtual Congress , Chief Executive Officer , Chief Financial Officer , Basilea Pharmaceutica , Marketing Authorization Applications , New Drug Application , Qualified Infectious Disease Product , Chief Medical Officer , Corporate Communications , Public Health , Products And Services , Government Regulations ,